Contact Us
Drug Search Results
More Filters [+]

Artemether

Alternative Names: artemether, artemeter
Latest Update: 2024-08-12
Latest Update Note: Clinical Trial Update

Product Description

an alternative artemisinin derivative. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25209020/)

Mechanisms of Action: ATPase Binder

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Sublingual

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | China | Colombia | Ecuador | Egypt | France | Germany | Greece | India | Indonesia | Ireland | Japan | Malaysia | Netherlands | New Zealand | Pakistan | Peru | Portugal | Slovenia | South Africa | Spain | Sweden | Switzerland | Thailand | Ukraine | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Ministry of Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Artemether

Countries in Clinic: Bangladesh, Burkina Faso, Cambodia, Congo, Gambia, Guinea, Kenya, Niger, Nigeria, Rwanda, Tanzania, Thailand

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Malaria, Falciparum

Phase 1: HIV Infections|Hepatitis B|Pregnancy Outcomes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ALAQ

P1

Recruiting

Hepatitis B|HIV Infections|Pregnancy Outcomes

2026-08-31

CHMI-TransMod

P2

Suspended

Malaria, Falciparum

2025-12-01

DeTACT-Africa

P3

Recruiting

Malaria, Falciparum

2024-03-15

2023-000804-21

P3

Active, not recruiting

Malaria, Falciparum

2023-08-31

Recent News Events

Date

Type

Title

04/26/2024

News Article

 Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa

12/14/2023

News Article

 Investment of Approximately USD 8.8 Million for New Drug Development Against Malaria to Partners Including Marubeni and Eisai

12/14/2023

News Article

 Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs

11/27/2023

News Article

 Global Artemisinin Combination Therapy Market Report 2023 - Growing R&D of New Artemisinin Combination Therapies

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions